Golnaz Atefi’s 1,000km Skating Journey for Dementia Research
Dementia ResearcherInterview with Golnaz Atefi about her unique plans to roller skate 1000km in 30 days across Europe, in support of research and World Alzheimer’s Month.
Research News
Lecanemab recieves NICE rejection
NICE draft recommendation says Lecanemab benefits are too small to support approval after looking at cost and clinical trials evidence
Lecanemab recieves UK MHRA approval
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a product licence for lecanemab (Leqembi) for use in the early stages of Alzheimer’s
How we’ve succeeded in recruiting older hospital patients onto our trial
NIHRDr McColl and Prof Pendlebury explain how they’ve tackled the challenge of recruiting older, frail patients with multiple conditions to trials within acute care in hospitals
Memory Services Spotlight Audit 2023
The 2023 National Audit of Dementia Memory Services reveals rising wait times, service inconsistencies, and urgent needs for equitable dementia care and support
Novel sequencing approaches highlight role of brain gene activity in Alzheimer’s
Research reveals that the activity of different versions of genes expressed in the brain is associated with the accumulation of tau, a hallmark of Alzheimer’s
Dementia Lancet Commission 2024
Updated for 2024 – New Lancet Commission Report on Dementia prevention, intervention, and care led by Professor Gill Livingston
Endorsed – New method for evaluating severity of Alzheimer’s
The IMI AMYPAD project robustly assessed a numerical scale from 0-100 that can be used to quantitatively compare brain scans of Alzheimer’s patients.
GLP-1 Drug Liraglutide May Protect Against Dementia
Alzheimer's AssociationResearch reported at AAIC shows a GLP-1 agonist — the class of drugs shown to help with diabetes and weight loss may also protect the brain.
Learn How the MND Association is fighting MND
Read the new report from the MND Association – learn about their work on translational research, work funded, partnerships and about new trial designs.
Blood Test may improve Alzheimer’s diagnosis in primary care
Research reported at AAIC shows blood tests can be 90% accurate in diagnosing Alzheimer’s disease and could be use in primary care and memory clinics.
EU regulator rejects Lecanemab
The European Medicines Agency (EMA) has rejected a licence for Lecanemab – a drug shown to work on clearing amyloid plaques.